NEW YORK – Lex Diagnostics said on Monday that it has obtained 510 (k) clearance and CLIA waiver from the US Food and Drug Administration for its Velo point-of-care molecular diagnostic system and an ...

The system is intended for use in urgent care clinics, primary care settings, physician office laboratories, and pharmacies.

The Canada Point of Care Molecular Diagnostics Market, valued at USD 350 million in 2024, is projected to reach USD 560 ...

Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that ...

The COVID-19 pandemic led to a disruption of infection rates of many common respiratory diseases in children. However, the aftereffects of the pandemic, once restrictions were removed, remain unclear.

SALT LAKE CITY, Nov. 18, 2025 /PRNewswire/ --Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...

First-ever ISO 16140-2 validated multiplex PCR assay for simultaneous detection of Salmonella and Cronobacter Camarillo, CA – May 20, 2025 – Hygiena®, a global leader in One Health Diagnostics® and ...

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system ...

QIAcuity digital PCR now offers ability for simultaneous detection of up to 12 targets from one biological sample, a more than two-fold increase from prior capability ...